Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 43598-122

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 43598-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

Packaging label for Clopidogrel Tablets USP 300 mg oral film-coated tablets by Dr. Reddy's Laboratories Inc. The label indicates a 30-tablet unit dose pack (5 blister cards with 6 tablets each). Storage instructions and a QR code for the Medication Guide are visible. The label includes NDC 43598-122-59 and specifies the distributor as Dr. Reddy's Laboratories, made in India.*

FDA Label Image

Container1 (Container1)

Clopidogrel Tablets, USP 75 mg film-coated tablets label from Dr.Reddy's Laboratories Inc. The label indicates the Rx only status, package size of 30 tablets, and includes dosage and storage instructions. The NDC number 43598-121-30 is visible, along with a QR code and barcode for product identification.*

FDA Label Image

Container2 (Container2)

Label for Clopidogrel bisulfate Tablets, USP 300 mg, film-coated oral tablets. The package contains 30 tablets and is labeled by Dr. Reddy's Laboratories Inc. The label includes storage instructions, a barcode, and a reference to the medication guide for patients.*

FDA Label Image

Figure1 (Figure1)

A forest plot illustrating the effect of co-administered proton pump inhibitors (PPI) on the active metabolite area under the curve (AUC) for Clopidogrel bisulfate. The graph shows mean values with 90% confidence intervals for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, plotted along a horizontal axis ranging from 0.4 to 1.4.*

FDA Label Image

Figure2 (Figure2)

A cumulative event rate line graph comparing Clopidogrel plus aspirin versus placebo plus aspirin over 12 months of follow-up. The x-axis represents months of follow-up from 0 to 12, and the y-axis shows cumulative event rate percentage from 0% to 16%. The Clopidogrel line demonstrates a lower cumulative event rate compared to placebo throughout the follow-up period. Statistical significance (P=0.00009) is noted, with a footnote mentioning other standard therapies used as appropriate.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart summarizing hazard ratios with 95% confidence intervals for Clopidogrel bisulfate versus placebo across various subgroups. Subgroups include age, gender, race, cardiovascular history, diabetes, medication use, and overall results. The plot visually compares the estimated effect of Clopidogrel against placebo for multiple categories, showing which treatment favors outcomes.*

FDA Label Image

Figure4 (Figure4)

A line graph comparing the percentage of deaths before first discharge between placebo and Clopidogrel over 28 days since randomization. The graph shows cumulative death rates and indicates a 7% proportional risk reduction with Clopidogrel versus placebo, annotated with specific death counts for each group.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier plot showing the cumulative percentage of patients with death, reinfarction, or stroke over 28 days from randomization. Two curves compare placebo and clopidogrel, with placebo reaching about 10.1% events and clopidogrel about 9.2%, indicating a 9% proportional risk reduction (p=0.002). The x-axis represents days since randomization, and the y-axis shows the percentage with events before first discharge.*

FDA Label Image

Figure6 (Figure6)

A forest plot chart depicting odds ratios with 99% confidence intervals for the effectiveness of Clopidogrel bisulfate compared to placebo across various subgroups including gender, age groups, hours since onset, systolic blood pressure (SBP) categories, heart rate ranges, and fibrinolytic agent usage. The plot visually summarizes the relative favorability of Clopidogrel or placebo within each subgroup and overall.*

FDA Label Image

Figure7 (Figure7)

A line graph depicting cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up for Clopidogrel and Aspirin. Clopidogrel shows a lower cumulative event rate compared to Aspirin, with a reported p-value of 0.045 indicating statistical comparison.*

FDA Label Image

Figure8 (Figure8)

A forest plot comparing the hazard ratios with 95% confidence intervals of Clopidogrel bisulfate versus Aspirin across different qualifying conditions including Stroke, Myocardial Infarction (MI), Peripheral Artery Disease (PAD), and Overall. The plot displays numerical data of events for each treatment and visually indicates which treatment the hazard ratio favors for each condition.*

FDA Label Image

Structure (Structure)

Chemical structure of Clopidogrel bisulfate, showing its molecular arrangement including a thiophene ring, a bicyclic ring system, and a chlorophenyl group, along with the associated bisulfate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.